Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia

Ann Hematol. 2020 Oct;99(10):2455-2456. doi: 10.1007/s00277-020-04087-2. Epub 2020 May 25.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antifungal Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Drug Resistance, Multiple, Fungal
  • Drug Substitution
  • Fatal Outcome
  • Febrile Neutropenia / complications
  • Febrile Neutropenia / drug therapy
  • Female
  • Filgrastim / therapeutic use
  • Fluconazole / therapeutic use
  • Humans
  • Immunocompromised Host
  • Invasive Fungal Infections / drug therapy
  • Invasive Fungal Infections / etiology*
  • Invasive Fungal Infections / microbiology
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Middle Aged
  • Piperacillin, Tazobactam Drug Combination / therapeutic use
  • Purines / administration & dosage
  • Purines / adverse effects
  • Quinazolinones / administration & dosage
  • Quinazolinones / adverse effects
  • Recurrence
  • Rituximab / administration & dosage
  • Rituximab / adverse effects
  • Scedosporium / drug effects
  • Scedosporium / isolation & purification*
  • Triazoles / therapeutic use
  • Valacyclovir / therapeutic use
  • Vidarabine / administration & dosage
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives

Substances

  • Antifungal Agents
  • Purines
  • Quinazolinones
  • Triazoles
  • Piperacillin, Tazobactam Drug Combination
  • Rituximab
  • posaconazole
  • Cyclophosphamide
  • Fluconazole
  • Vidarabine
  • Valacyclovir
  • fludarabine
  • Filgrastim
  • idelalisib

Supplementary concepts

  • scedosporiosis